Jin S, et al. (2020) 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clin Cancer Res 32054729

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S52-p - eIF2-alpha (human) ▲

Modsite: MILLsELsRRRIRsI SwissProt Entrez-Gene Orthologous residues eIF2‑alpha (human): S52‑p, eIF2‑alpha (mouse): S52‑p, eIF2‑alpha (rat): S52‑p, eIF2‑alpha (rabbit): S51‑p, eIF2‑alpha (fruit fly): S51‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  leukemia, acute myelogenous leukemia, acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b), acute myeloblastic leukemia, with granulocytic maturation (M2) Relevant cell lines - cell types - tissues:  Kasumi-1 (myeloid), MV4-11 (macrophage), OCI-AML5 (myeloid) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes AzaC increase Downstream Regulation Effect of modification (process):  apoptosis, induced, transcription, induced